Skip to main content
Log in

Alterations of fibrin network structure mediated by dermatan sulfate

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Dermatan sulfate (DS) is well-known for its anticoagulant activity through binding to heparin cofactor II (HCII) to enhance thrombin inhibition. It has also been reported that DS has a profibrinolytic effect. We have evaluated the effects of DS solutions (4–20 μg/mL) on the formation (by kinetic studies), structure (by electron microscopy and compaction assays) and lysis (with urokinase-type plasminogen activator) of plasma fibrin networks. The results showed that DS significantly prolonged the lag phase and decreased the fibrin formation rate and the optical density of the final networks versus control, in a concentration dependent way. DS-associated networks presented a minor network percentage compared with control, composed of lower number of fibers per field, which resulted significantly thinner and longer. Moreover, DS rendered gels more sensible to rupture by centrifugal force and more susceptible to lysis. When fibrin formation kinetic assays were performed with purified fibrinogen instead of plasma, in the absence of HCII, the optical density of final DS-associated networks was statistically lower than control. Therefore, a direct effect of DS on the thickness of fibers was observed. Since in all in vitro assays low DS concentrations were used, it could be postulated that the fibrin features described above are plausible to be found in in vivo thrombi and therefore, DS would contribute to the formation of less thrombogenic clots.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Casu B (1991) Structural features and binding properties of chondroitin sulfate, dermatan sulfate and heparan sulfate. Semin Thromb Hemost 17:9–14

    PubMed  Google Scholar 

  2. Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B (1992) An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 89:321–326

    Article  PubMed  CAS  Google Scholar 

  3. Delorme MA, Saees N, Sevick A, Mitchell L, Berry L, Johnston M, Andrew M (1993) Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis. Blood 82:3380–3385

    PubMed  CAS  Google Scholar 

  4. Rossi E, Duboscq C, Peragallo M, Kordich L (1997) Heparin cofactor II (HC II) and dermatan sulfate plasmatic levels in acute burnt patients. Thromb Haemost Suppl:435

  5. Saito A, Munakata H (2007) Analysis of plasma proteins that binds to glycosaminoglycans. Biochim Biophys Acta 1770:241–246

    Article  PubMed  CAS  Google Scholar 

  6. Rau J, Mitchell J, Fortenberry Y, Church F (2011) Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost 37:339–348

    Article  PubMed  CAS  Google Scholar 

  7. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourão PA (2005) Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 1740:45–53

    Article  PubMed  CAS  Google Scholar 

  8. Han JH, Cote HCF, Tollefsen DM (1997) Inhibition of meizothrombin and meizothrombin(des F1) by heparin cofactor II. J Biol Chem 272:28660–28665

    Article  PubMed  CAS  Google Scholar 

  9. Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI (2001) Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276:20959–22065

    Article  PubMed  CAS  Google Scholar 

  10. Iacoviello L, D’Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB (1996) Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 76:1102–1107

    PubMed  CAS  Google Scholar 

  11. Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B (1992) Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 68:637–641

    PubMed  CAS  Google Scholar 

  12. Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. Pharmacoeconomics 19:57–68

    Article  PubMed  CAS  Google Scholar 

  13. Imberti D, Verso M, Silvestrini E, Taliani MR, Agnelli G (2003) Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost 1:2696–2697

    Article  PubMed  CAS  Google Scholar 

  14. Castañon MM, Gamba C, Kordich LC (2007) Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators. Thromb Res 120:745–752

    Article  PubMed  Google Scholar 

  15. Stirling Y, Woolf L, North W, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52:176–182

    PubMed  CAS  Google Scholar 

  16. Wickström K, Edelstam G, Löwbeer C, Hansson L, Siebahn A (2004) Reference intervals for plasma levels of fibrinectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31–40

    Article  PubMed  Google Scholar 

  17. Delorme M, Burrows R, Ofosu F, Andrew M (1992) Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost 18:81–90

    Article  PubMed  CAS  Google Scholar 

  18. Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U (1996) Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 82:109–117

    Article  PubMed  CAS  Google Scholar 

  19. Giri TK, Tollefsen DM (2006) Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 107:2753–2758

    Article  PubMed  CAS  Google Scholar 

  20. Weisel JW, Litvinov RI (2008) The biochemical and physical process of fibrinolysis and effects of clots structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6:161–180

    Article  PubMed  CAS  Google Scholar 

  21. Lauricella AM, Quintana I, Castañon M, Sassetti B, Kordich L (2006) Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 17:181–186

    Article  PubMed  CAS  Google Scholar 

  22. Nair CH, Shats EA (1997) Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to crosslinking. Thromb Res 88:381–387

    Article  PubMed  CAS  Google Scholar 

  23. Colliec S, Fischer AM, Tapon-Bretaudiere J, Boisson C, Durand P, Jozefonvicz J (1991) Anticoagulant properties of a fucoidan fraction. Thromb Res 64:143–154

    Article  PubMed  CAS  Google Scholar 

  24. Weisel JW, Veklich Y, Collet JP, Francis CW (1999) Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 82:277–282

    PubMed  CAS  Google Scholar 

  25. Wolberg AS, Gabriel DA, Hoffman M (2002) Analysing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 13:533–539

    Article  PubMed  CAS  Google Scholar 

  26. Jones M, Gabriel DA (1988) Influence of subendothelial basement membrane components on fibrin assembly. J Biol Chem 263:7043–7048

    PubMed  CAS  Google Scholar 

  27. Litvinov RI, Yakovlev S, Tsurupa G, Gorkun OV, Medved L, Weisel JW (2007) Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 46:9133–9142

    Article  PubMed  CAS  Google Scholar 

  28. Weisel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5(Suppl. 1):116–124

    Article  PubMed  CAS  Google Scholar 

  29. Undas A, Ariëns R (2011) Fibrin clot structure and function. A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:88–99

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from the Universidad de Buenos Aires (UBACyT 01/W998), Argentina.

Conflict of interest

All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ana María Lauricella.

Additional information

María Mercedes Castañon—in memory.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lauricella, A.M., Castañon, M.M., Kordich, L.C. et al. Alterations of fibrin network structure mediated by dermatan sulfate. J Thromb Thrombolysis 35, 257–263 (2013). https://doi.org/10.1007/s11239-012-0804-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0804-9

Keywords

Navigation